1 / 24

The Fight Against Measles

The Fight Against Measles. The Present Situation The Strategies The Vaccination The Controversy . Recent Outbreaks. About 20 million cases each year around the globe. 2011 UK- 804 cases Ireland – 173 cases Europe - more than 26,000 cases 8 deaths

verdad
Télécharger la présentation

The Fight Against Measles

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Fight Against Measles The Present Situation The Strategies The Vaccination The Controversy

  2. Recent Outbreaks • About 20 million cases each year around the globe. • 2011 UK- 804 cases Ireland – 173 cases Europe - more than 26,000 cases 8 deaths 24 cases measles encephalitis • Africa and Asia , remains one of leading causes of death in children. – WHO - 164,000 people died from measles in 2008, most younger than 5 years old.

  3. Recent Outbreaks (2) • Increase in measles cases and deaths in recent months • Prevalent in famine and drought areas • Unvaccinated children forced to live in cramped refugee camps • Somalia – 24%of 1yr olds immunized in country

  4. Eradication • Increase in US cases • over 92% population vaccinated • Dropped due to importation of disease from WHO European Regions and South East Asian regions. • 33 countries in WHO European Region have increased measles cases

  5. MMR Vaccine • Developed in 1960s by Maurice Hilleman • 3 live attenuated viruses • First dose ~1 year, second ~5 years. • Before vaccination, measles “as inevitable as death and taxes”. • Now contracted by <1% of individuals under 30 in countries with routine childhood vaccination • Prevents illness, disability, death.

  6. WHO Strategy 1994 - 2004 • Aim: Vaccinate >90% in all districts • All children to get second dose • 71% of targeted children in 1999 -> 76% in 2004 • Sub-Saharan Africa – 49% -> 65% • South Asia – 54% -> 61% • 2004 – 168 counties (88%) offered second round

  7. MMR in Ireland • First dose at 12 months • Second dose (not booster) at 4-5 years • Through school/HSE or GP • Recent outbreaks of measles and mumps due to missed second dose

  8. Vaccination Strategy- Ireland • 1985 - Monocomponent measles vaccine introduced- 10,000 cases in that year reduced to 201 in 1987 • 1988- combined MMR introduced -12-15months • 1992- Second dose recommended- 10-15 years • 1999- Age of second dose reduced to 4-5 years • Childhood vaccination Schedule for children born after 1st July 2008- Free From the Department of Health, HSE • 12months from GP • 4-5 yrs from GP or in School • Primary School Immunisation Programme

  9. Outbreak in 1993- affected 4,000 people • 2000- 1,600 cases resulted in 3 deaths • From 2001 to 2006 – 1,562 cases • Rapid spread during these outbreaks due to: • Incomplete vaccination coverage • Susceptible pool of older unvaccinated children • Today- 221cases reported in 2011, so far (411 in 2010) • 85% occurred in North Dublin City • 90% of children have received 1st dose by 24months

  10. W.H.O-Measles Eradication • Global mortality reduced by 78% , from estimated 733 000 deaths in 2000 to an estimated 164 000 deaths in 2008-78% • The WHO region of America has • sustained elimination since 2002 • The WHO has set a target of elimation of measles in remaining 4 out of 5 WHO regions by 2020. • This can only be achieved by Increasing routine immunization coverage • improving surveillance systems • political and financial commitment

  11. Vaccination • There are two treatments to protect against measles: • MMR: measles, mumps and rubella vaccine. • MMRV: measles, mumps, rubella, and varicella vaccine.

  12. Development • First virus was obtained from David Edmonston in 1954. • The virus strain was grown in chick embryos. • Made the virus more suited to chicks than humans • Similar attenuated vaccines around this time were developed. • From nucleotide tests all vaccines were shown to be similar. • At present the MMR vaccine has a 95% efficiency.

  13. WHO: Eradiation Policy • Control: reduce incidence of disease. Due to 95% efficiency a two dose strategy is need to prevent an accumulation of susceptible individuals. • In 2010, about 85% of the world's children received one dose of measles vaccine by their first birthday through routine health services – up from 72% in 2000. Two doses of the vaccine are recommended to ensure immunity, as about 15% of vaccinated children fail to develop immunity from the first dose.

  14. Measles Vaccine • Children should be vaccinated with the MMR vaccine 12 to 15 months after birth and should receive a second dose at 4-5 year usually before the child enters school. • Before the vaccination programme was implemented in USA, between 3 to 4 million people were infected each year, with 400 to 500 dying • Measles is a highly contagious virus and was estimated there was 242,000 Measles deaths which equals 27 deaths every hour.

  15. MMR Vaccine Risks • The vaccine like many vaccines can cause allergic reactions, most people however do not have any problems with it. • Mild problems: fever (1 in 6 doses), mild rash ( 1 in 20) or rare swelling of glands. • Moderate problems: seizure (1 in 3,000 doses), temporary pain in joints ( 1 in 4 teenage and adult women) and temporary low platelet counts which can lead to a bleeding disorder ( 1 in 30,000 doses). • Sever problems: 1 in 1 million: deafness, long-term seizures or comas and permanent brain damage.

  16. Less safe if recipient... • Has a fever • Is taking steroids • Has had another live attenuated vaccine in the last three days • Is receiving chemotherapy/radiotherapy • Has a compromised immune system

  17. Problems with Vaccine Developing Countries Immunodeficiency • Individuals with low immune responses can’t handle certain vaccines due to the presence of attenuated or live virus. • Presence of maternal antibodies during first 9 months of life reduces efficiency of immunization. • Measles virus infects children by the respiratory tracts and little of the maternal antibodies will be transduced onto mucosal surfaces

  18. Advancements • Aerosol delivery and high titre vaccinations to overcome problems in vaccinating young infants. • Recombinant virus • Immune-stimulating complexes • DNA vaccination

  19. Controversy:Wakefield et al. 1998

  20. Wakefield et al. 1998 • 12 Children with Gastrointestinal symptoms, lost acquired skills including communication • In 8 children, parents and/or physicians linked onset of behavioural problems with MMR • Main cause of public concern

  21. Media Coverage • Wakefield: “I cannot support the continued use of these vaccines in combination…” • Public uproar & slump in MMR vaccinations • Brian Deer Sunday Times investigation 2003-2011 • Prof.John O’ Leary slander

  22. Evidence against autism link & aftermath of investigation • Horniget al. 2008 replications • Wakefield foul play

  23. References • http://www.immunisation.ie/en/Downloads/NIACGuidelines/PDFFile_15482_en.pdf • http://www.irishhealth.com/article.html?id=780 • http://www.immunisation.ie/en/Downloads/PDFFile_15371_en.pdf • http://www.who.int/immunization_monitoring/diseases/measlesreportedcasesbycountry.pdf • http://www.immunisation.ie/en/ChildhoodImmunisation/PrimaryImmunisationSchedule/ • http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_18-en.pdf • http://www.who.int/immunization/newsroom/news_wha_2010_measles_eradication/en/index.html • www.braindeer.com • http://www.who.int/mediacentre/factsheets/fs286/en/ • http://www.cdc.gov/vaccines/vpd-vac/measles/default.htm • http://www.immunisation.ie/en/ChildhoodImmunisation/VaccinePreventableDiseases/MMR/ • J. Wakefield, S. H. Murch, A. Anthony, J. Linnell, D. M. Casson, M. Malik, M. Berelowitz, A. P. Dhillon, M. A. Thomson (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. • T. F. Wild (1999) Measles vaccines, new developments and immunization strategies. Vaccine 17; 1726-1729.

More Related